Ashwin Varma, MD

@varma_ashwin97

Currently: PGY-1 Former: Associate @BCG, Clinical Trials @MDAndersonNews, External R&D @Celgene, Summer Associate, @Lux_Capital. Views my own.

Joined September 2012

5KFollowing

2KFollowers

Pinned

Ashwin Varma, MD@varma_ashwin97 · 23 h

Frustrating that I can find no more information on the various innovations here - radial flow pin fins and GEs program on film cooling.

varma_ashwin97's tweet image. Frustrating that I can find no more information on the various innovations here - radial flow pin fins and GEs program on film cooling.

216

Pinned

Ashwin Varma, MD@varma_ashwin97 · Jul 24

Does anyone know whether the industry was at all interested in developing TGF based traps and / or antagonists for PAH before Acceleron came onto the scene?

227

Ashwin Varma, MD@varma_ashwin97 · Jul 26

I'll still never get over the fact that both the benefits of SGLT2 in HF patients and CKD patients - both irrespective of T2D status - was in absolutely no way predicted by any of the initial developers.

ddrug hunter@drughunter_com · Jul 25

The Evolution of SGLT2 Inhibitors: From Apple Tree Bark to Clinical Impacts Beyond Glycemic Control | drughunters.com/3H2kuXq The global epidemic of obesity and T2DM continues to grow at an alarming pace. In the United States alone, more than 38 million—nearly 1 in 10…

1.0K